Scientific American examines worldwide spread of drug-resistant gonorrhea

NewsGuard 100/100 Score

Scientific American examines how strains of cephalosporin-resistant gonorrhea have "been emerging in Japan, and moving east and west from there, for at least a decade." The magazine writes, "Rapid international travel allowed the resistance mutation to hopscotch the globe," noting antibiotic-resistant strains that have been identified in Sweden, England, Norway, the Philippines, Spain, and France. "'We can't go back to older antibiotics,' says Peter Leone, who is board chair of the National Coalition of STD Directors and medical director of North Carolina's STD prevention program. 'Once resistance emerges in gonorrhea, it is there for good. Cephalosporins are all we have left,'" he added, according to Scientific American. The magazine writes that efforts "to educate physicians and patients, to track resistant strains and to develop new treatments ... must be carefully targeted and well coordinated with one another," and concludes, "If not, truly untreatable gonorrhea, and its expensive, destructive consequences, could be the worldwide result" (McKenna, 5/4).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    CARB-X awards $1.8 million to Visby Medical to develop a portable rapid PCR test for gonorrhea